Invokana: Trial Update
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm.
Invokana manufacturer, Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has netted almost $1 billion in profits from Invokana in the last year alone. Meanwhile, the number of individuals injured by Invokana have begun to accumulate. They have begun to file consumer protection lawsuits against the pharmaceutical giant.
At the present time, The Michael Brady Lynch Firm is concentrating on Pennsylvania. This is the location where our cases are pending against the makers of Invokana. As of June 2016, approximately 41 cases were filed in Philadelphia by plaintiffs that live all across the country. This will most likely mean a mass tort consolidation at the Federal level is imminent.
This does not mean that Johnson & Johnson is rolling over. They already filed motions to remove their name from the lawsuits along with attempting to move cases to New Jersey. Johnson & Johnson are gunning for New Jersey since the company just had a talcum powder litigation dismissed there. The manufacturer is hoping a judge will dismiss these cases as well.
In yet another case pending in Philadelphia County, Johnson & Johnson is attempting to assert a Federal preemption argument. In that case, the drug maker is testing other defense strategies that it may implement on a large scale as the litigation moves forward.
No matter the tactic that Johnson & Johnson attempts, we will do everything in our power to help our clients achieve justice.